WSGR not for any penny stock except EPGL.. please name your dogs and firms who have hired WSGR.

NO CHOICE but Millionaire forever

By owning Inwith

EPGL patents in 500 millions to Billions potential VALUES:

Based on PWC and others historical market patents buyout, licensing, or infringements.

https://www.pwc.com/us/en/forensic-services/publications/assets/2017-patent-litigation-study.pdf

Year Plaintiff Defendant Technology Award (in $M)
2016 Idenix Pharmaceuticals LLC Gilead Sciences Inc. Hepatitis C drugs $2,540
2009 Centocor Ortho Biotech Inc. Abbott Laboratories Arthritis drugs $1,673
2007 Lucent Technologies Inc. Microsoft Corp. MP3 technology $1,538
2012 Carnegie Mellon University Marvell Technology Group Noise reduction on circuits for disk drives $1,169
2012 Apple Inc. Samsung Electronics Co. Smartphone software $1,049
2012 Monsanto Company E.I. Du Pont De Nemours and Co. Genetically modified soybean seeds $1,000
2005 Cordis Corp. Medtronic Vascular, Inc. Vascular stents $595
2015 Smartflash LLC Apple Inc. Media storage $533
2004 Eolas Technologies Inc. Microsoft Corp. Internet browser $521
2011 Bruce N. Saffran M.D. Johnson & Johnson Drug-eluting stents $482

http://www.bustpatents.com/awards.html

Amount Year Parties Legal Action Technology Reference
$21,000,000,000 2015 Pharmacyclics <-- AbbVie Buyout Drugs (Cancer) NYT, Mar 2015
$16,700,000,000 2015 Altera <-- Intel Buyout Electronics (FPGA) Fortune2015
-$10,980,000,000
(down 47%) 2016 LinkedIn Missed Earnings Social Network WSJ2016
$10,960,000,000 2015 Salix Pharmaceuticals <-- Valeant Pharmaceuticals Buyout Drugs (Gastrointestinal) Reuters2015
$10,100,000,000 2015 Salix Pharmaceuticals <-- Valeant Pharmaceuticals Buyout Drugs (Gastrointestinal) Reuters Feb2015
$8,700,000,000 2013 Bausch & Lomb <-- Valeant Pharmaceuticals Buyout Eyecare Bloomberg2013
$8,400,000,000 2015 Synageva BioPharma <-- Alexion Pharmaceuticals Buyout Drugs (Rare Diseases) IndWeek2015
-$8,000,000,000
(down 10%) 2015 AbbVie (ABBV) FDA warning Drugs (Hepatitis C) WSJ2015
$7,650,000,000 2014-2032 Int. Olympic Committee <-- NBC Universal C.License Sports IOC2014
-$7,000,000,000
(down 79%) 2015 Eli Lilly (LLY) FDA Phase III test failure Drug (cardiovascular) WSJ2015
$5,900,000,000
(+ $646 million) 2015 Dyaz Corp. <-- Shire P.Buyout Pharmaceutical NYT2015
$5,800,000,000
(+ 50%) 2016 Alere <-- Abbott Buyout Medical - PoS Diagnostics MW2016
-$5,300,000,000
(down 7%) 2016 Boeing Accounting Problems Airplanes CNBC2016
-$4,000,000,000
(down 44%) 2016 Alkermes (ALKS) Clinical trial failure Drugs (Depression) BostonGlobe2016
$3,300,000,000 2014 Cystic Fibrosis Foundation <-- Royalty Pharma P.License Pharmaceutical WSJ, Dec 2014
$3,250,000,000 2015 Dish Network <-- American taxpayers Loopholes Communications NYT, Feb 2015
$3,250,000,000 2013 Elan Pharmaceuticals <- Biogen Idec P.Buyout Pharmaceutical Forbes, Feb 2013
$2,900,000,000 2014 Google <-- Lenovo P.Buyout (L buys Motorola
Mobility, gets 2000+ patents) Electronics PCW2014
$2,700,000,000 2015 ZS Pharma <-- AstraZeneca P.Buyout Pharmaceuticals NYT2015
$2,500,000,000 2002 Major League Baseball <-- Fox Television C.License Sports BCB1000
$2,300,000,000 2015 Ikaria <-- Mallinckrodt P.Buyout Drug (infant) NYT, Mar2015
$2,150,000,000 2013 Pfizer <-- Teva and Sun Pharma P.Settlement Drug Fox, June 2013
$1,740,000,000
$350,000,000 upfront
$340,000,000 regulator
$1.05 billion milestone 2015 Five Prime <-- Bristol-Myers Squibb P.License Drug (cancer) GEN2015
$1,725,000,000 1996 NCAA Basketball <-- CBS C.License Sports BCB0698
$1,540,000,000 2014 Carnegie Mellon Univ. <-- Marvell Technology P.Lawsuit Electronics NYT2014
$1,450,000,000 2015 IOC - Olympics <-- Discovery EuroSport C.License 2018-2024 broadcast rights Money2015
$1,440,000,000 2014 European Union <-- Intel Antitrust Electronics NYT2014
-$1,400,000,000
(down 35%) 2015 Pandroa (P) Competition from Apple Music streaming NYT2015
$1,350,000,000 2005 Karlin Technology <-- Medtronics P.Settlement Medical NYT0504
$1,300,000,000+ 2015 Sorrento Therapeutics <-- NantPharma P.License Pharmaceutical JakPst2015
-$1,300,000,000
(down 80%) 2015 Chimerix (CMRX) FDA Phase III test failure Antiviral for transplants ValueWalk2015
-$1,300,000,000
(down 79%) 2015 Tetraphase Pharmaceuticals (TTPH) FDA Phase III test failure Drug (antibiotic) Barrons2015
$1,200,000,000 2015 U.S. FTC <-- Teva Pharmaceuticals Antitrust Generic Pharmaceuticals WSJ201505
~$1,200,000,000 2013 U.S. Open <-- Fox Sports C.License Sports Broadcast (golf) PGATOUR2013.
$1,100,000,000+ 2014 Edwards Lifesciences <-- Medtronic P.Settlement Medical Forbes2014
$1,100,000,000 2014 Fusion-IO <-- SanDisk Buyout Electronics USAToday2014
$1,000,000,000 2015 Sprout Pharmacueticals <-- Valeant Pharmacueticals P.Buyout Drug (female libido) WPost2015
$1,000,000,000
($300, then $200, then $500 million) 2015 GlaxoSmithKline <-- Novartis P.Buyout Drug (MS - ofatumumab) NYT2015
$1,000,000,000 2015 Juno Therapuetics <-- Celgene P.License Cancer Drugs NYT2015
$1,000,000,000 2013 Microsoft <-- Samsung P.License Software (Android) Verge2014
$1,000,000,000+ 2014 Songwriters <-- ASCAP C.Royalties Music NYT Mar2015
$1,000,000,000 2000 SnapTrack <-- Qualcomm Buyout Electronics SJMN0100
$975,000,000 2015 China <-- Qualcomm P.Antitrust Electronics NYT, Jan2015
$890,000,000 2012/2013 Apple <-- Samsung P.Lawsuit Software NY Times, 21 Nov. 2013
$873,000,000 1991 Polaroid <-- Eastman Kodak P.Lawsuit Chemical USPQ1617
$820,000,000 2001 Hallmark Entertainment <-- Crown Media C.Buyout Miniseries DV0401
$800,000,000+ (up 5.6%) 2015 Ericsson <-- Apple Computer P.Settlement Communications Reuters2015
-$770,000,000
(down 53%) 2015 Amicus Therapeutics (FOLD) FDA filing delay Drug (Galafold) WSJ2015
$761,000,000 [RealNetworks +34%] 2005 RealNetworks <-- Microsoft Antitrust Online Entertainment WSJ0511
$750,000,000 2016 Michael Jackson (estate) <-- Sony C.Buyout Music (Sony/ATV Catalog) NYT2016
$750,000,000 2016 Carnegie Mellon <-- Marvell Technology (up 6%) P.Settlement Semiconductors WSJ2016
$750,000,000 2005 Medinol <-- Boston Scientific Contracts/Designs Medical NYT0509
$700,000,000 (upto) 2015 Inovio <-- AstraZeneca P.License Cancer drug MarBus2015
$700,000,000 1997 Digital <-- Intel P.Lawsuit Computer IW1197
$650,000,000 2014 Ericsson <-- Samsung P.Settlement Electronics Reu201401
$626,000,000 2016 VirnetX <-- Apple P.Lawsuit Software ArsTech2016
($625,000,000) 2011 Mirror Worlds <-- Apple P.Lawsuit Software HuffPost, Apr 2011
$600 million 2015 NHL <-- MLB Advanced Media C.License Hockey broadcasts WSJ2015
$600,000,000 ($225 then $375) 2016 Padlock <-- Bristol-Myers Squibb P.Buyout Drugs (Automimmune) FierceBio2016
$600,000,000 2015 Johnson & Johnson <-- Boston Scientific BuyoutBreach Medical WSJ, Feb 2015
($593,000,000) 2011 Bruce Saffran <-- Johnson & Johnson P.Lawsuit Medical WSJ, Apr 2013
$560,000,000 2015 Naurex <-- Allergan P.Buyout Drug - ketamine variants
-$550,000,000+
(down 75%) 2015 Zafgen (ZFGN) FDA clinical trial failure (1 death) Drug (genetic disorder) BG2015
$548,000,000 2015 Apple <-- Samsung P.Lawsuit Electronics AppleInsider, Dec2015
$533,000,000 2015 Smartflash <-- Apple P.Lawsuit Electronics PCWorld, Feb2015
$525,000,000 2014 Civitas Therapeutics <-- Acorda Therapeurics P.Buyout Drug - Parkinson's Reut2014
$525,000,000 2012 Kodak <-- Intellectual Ventures P.Buyout Digital Imaging (1100 patents) New York Times, Dec. 2012
$512,000,000 2015 U.S. Government (FTC) <-- Teva Pharmaceutical Antitrust Generic Drug NYT0415
$505,000,000 2002 Igen International <-- Roche Holding P.Lawsuit Drugs WSJ0102
$500,000,000+ 1990 Texas Instruments <-- Toshiba P.Settlement Electronics EET1290
$500,000,000 2002 Paramount Pictures <-- KirchMedia C.License Movies LAT1202
$500,000,000 2002 City of Hope Nat Med Cent <-- Genentech P.Lawsuit Drugs SFC0602a
$500,000,000 1998 College Football <-- ABC C.License Sports BCB0698

I am sad for the poor rabbit, I am selling my EPGL stock tomorrow to create charity fund for “SAVE the RABBIT”.

See the video:

http://advances.sciencemag.org/highwire/filestream/201219/field_highwire_adjunct_files/2/aap9841_MovieS3.mp4


These South Korean researchers just developed technology smart contact lens in silicone Rubber. Their elastic material is “elastofilcon A” Page 9 in Materials and Method. They are not silicone hydrogel. EPGLmed.com says their technology is silicone hydrogel contact lens. Everyone wears Silicone Hydrogel contact lens.

Please find below more information about “Elastofilcon A”

https://books.google.com/books?id=K1mUBAAAQBAJ&pg=PA67&lpg=PA67&dq=Elastofilcon+A&source=bl&ots=oAAHpa21K&sig=Oc89ctkLKdqekR2dhllsGG38JpY&hl=en&sa=X&ved=0ahUKEwjvj4KoqfLYAhVQ6mMKHa86BawQ6AEIVTAJ#v=onepage&q=Elastofilcon%20A&f=false

Page 67
Here are the rewrite and highlight by me:

Silicone Rubber
Silicone rubber lenses have previously been used extensively for managing severe dry eye disease. ….They do not contain water and cannot dehydrate but they are prone to surface spoliation….Silflex and Silsoft (Elastofilcon A) is withdrawn and only Silsoft left in the market.

http://www.siliconehydrogels.org/editorials/previous_editorials_kathryn.asp

“Silicone hydrogel materials differ considerably from the silicone rubber (elastomer) lenses used for therapeutic or paediatric applications. Although silicone-elastomeric lenses offered exceptional oxygen transmission and durability, a number of major limitations are associated with their use in clinical practice. As fluid is unable to flow through the lens and the lens surfaces are hydrophobic, binding to the ocular surface is very likely.”

When I was a kid, I sell lemonade to make money.

May be they sell their technology to raise money?

Selling shares to raise money?
How do you know?

The public epgl shareholder get to go to WSRG to vote, better than going to DisneyWorld.

You can go to inwith twitter and see WSRG has signed agreement to represent Inwith, so as good as Wikipedia.

I see they are involved in proxy, Wikipedia.

Only way to own part of Inwith in the beginning like WSRG by regular people on the street is owning share in EPGL. Thats what it looks like.

Thats why there are only limited number of Billionaires in the world because what you are saying below is true. Only 1 in 100 chances.

“How about the nearly infinite times when the exact opposite was the case? “

It is very accurate because the subject I am discussing is “regrets of investing action” as I see a lot of crying pictures.

I never say buy Epgl, I say sell on Monday and make $800.

Ronald Gerald Wayne (born May 17, 1934) is an American retired electronics industry worker. He co-founded Apple Computer (now Apple Inc.) with Steve Wozniak and Steve Jobs, providing administrative oversight for the new venture. He soon, however, sold his share of the new company back to Jobs and Wozniak for $800 US dollars, and later accepted $1,500 to forfeit any claims against Apple (in total, equivalent to $9,498 in 2017). As of March 2017, if Wayne had kept his 10% stake in Apple Inc., it would have been worth over $75.5 billion.

Time to sell on Monday to make $800.

Kevin Massengill Raytheon alumni.....

EPGL knows their stuff, the right stuff...cant wait to see all their upcoming patents and their approval.

Go Epgl!!!!

Epgl Elastic Circuit is 3D stretchable circuit coverage, wow!!!, if they get it, thats good because contact lens is 3D, I dont see a flat 2D contact lens.

Go Epgl!!!

Epgl Elastic Circuit can be used for Electronic Contact Lens...that is nice

Go Epgl!!!

Electronic Contact lens is the product being developed by EPGL. Nobody can see contact lens in the picture here.

Apple product development are developed by their employee, so are Google/Samsung products. Since the investment is for Epgl, so who do we listen to....only Epgl employee in news release!! Non Epgl employee are not developing Epgl tech as they are not even qualified.

Go Epgl!!!

Let Epgl kick some A** This is USA, country with Freedom of Speech.

Epgl can do whatever they want. We investor are confident that there are reasons for what they are doing.

EPGL 200 days Moving Average $0.0337. It is going up and strong with all the head winds in the market. Its the support for now.

????:EPGL????1000????????????????????????????????????

One should invest base on price chart, it tells everything. All the DD is just hearsay. 0.04 support seems to hold so far, that's a good sign.

0.04 was an estimate. To be more accurate based on 50 days moving average, if the price goes down it should make the next stop 0.0473.

We call this negative divergent for the price topping. Ready for another round of down trend? Here comes retest of 0.04 support.

Could it be another pump and dump for another news release deadline? It looks like thats what all "EPGL stock price" does.

Conference is for educational purpose only. Apple does not go to conference to introduce their iphone 6 and watch. I am sure that we do not want EPGL to waste time teaching little kids at conference. I want EPGL to Develop and Sell Sell Sell to make us a lot & lots of Money and also kick some *** at the same time.

Epgl at least can offer Kung Pao lunch.

I only have Epgl price chart from google finance. Let's see if your analysis comes true.

Epgl support 0.04

Epgl stock rising up to Aug 29 is filled with trader. Epgl still does not have enough long term buyer. The price keeps dropping as the selling continues.

Yeah man, but remember, cat has 8 lives left.

Next support is $0.04

Epgl stock is experiencing dead cat bounce from Aug 29 news release. The sell off is not done yet, we have to wait for a few more days till the cat stop bouncing.

You should also tweeted to Jim Cramer to ask that now knowing COO is also in advance lens development race, should we be buying COO stock too?

I wonder what PWC response is with all this? A statement release from them would be great!

Is Epgl becoming Crazy? I thought I have heard about crazy things before, is history repeating itself?

Apple's 1997 Think Different campaign was launched not long after Steve Jobs returned to the company he founded. It began with these words:
"Here's to the crazy ones, the misfits, the rebels, the troublemakers, the round pegs in the square holes ... the ones who see things differently -- they're not fond of rules, and they have no respect for the status quo. ... You can quote them, disagree with them, glorify or vilify them, but the only thing you can't do is ignore them because they change things. ... They push the human race forward, and while some may see them as the crazy ones, we see genius, because the people who are crazy enough to think that they can change the world, are the ones who do."

Usually if your wife think you are nuts, then you are investing correctly in Epgl. Like Warren Buffet always say, buy when everyone is fearful!

Not the value, but the percentage, 10% at issue, which is majority if they are new stock holder. If Epgl is sold for $1 billion, then only $100 million for the 10%.

Float is only 10% of total shares. Sow how can we make money if buy out? If epgl is sold for $1million, float owner only get $100k, not much to retire for all of us.

$1.50 is support